The French EsoGastricTumours Data Base
FREGAT
National Oesophageal and Gastric Carcinomas Data Base Construction: the FREGAT (French EsoGastric Tumours) Data Base
2 other identifiers
observational
15,000
1 country
31
Brief Summary
This retrospective study aims at evaluating the outcomes of gastrointestinal stromal tumor after surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2014
Longer than P75 for all trials
31 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2014
CompletedFirst Submitted
Initial submission to the registry
August 13, 2015
CompletedFirst Posted
Study publicly available on registry
August 18, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 1, 2027
September 11, 2020
September 1, 2020
12.9 years
August 13, 2015
September 10, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
DIsease free survival
5 year disease free survival
Secondary Outcomes (5)
overall survival
5 year overall survival
recurrence rate
5 year recurrence rate
Total number of patients with complications
from the time between inclusion and occurrence of the event, for the duration of 3 years
Total number of complications
from the time between inclusion and occurrence of the event, for the duration of 3 years
Death
from the time between inclusion and occurrence of the event, for the duration of 3 years
Eligibility Criteria
All patients with gastroesophageal cancer diagnosed and treatment-naïve, if not receiving neoadjuvant treatment in a participating center will be included after acceptance and signature of consent, whether operated or not, whatever histologic type, tumor stage, and the therapeutic strategy.
You may qualify if:
- esophageal cancer, gastric or gastroesophageal junction diagnosed biopsy , regardless of the subtype of cancer, tumor stage or treatment envisaged.
- Naive treatment for this cancer,
- Naive treatment for this cancer , failing that received neoadjuvant treatment ,
- Male or female ≥ 18 years.
- social protection scheme .
- sign a free and informed consent for blood sampling , the different questionnaires and the collection of patient information.
You may not qualify if:
- Male or female aged ( e) under 18 years.
- Private person of liberty or under supervision (including guardianship ) .
- People who do not speak French.
- Major Nobody unable to consent .
- Patient FREGAT already included in the base.
- Patient Refusal .
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital, Lillelead
- French Eso-Gastric Tumors Working Groupcollaborator
- National Cancer Institute, Francecollaborator
Study Sites (31)
Chu Amiens Picardie
Amiens, France
Chru Besancon
Besançon, France
Hu Paris Site Avicenne Aphp
Bobigny, France
Chu de Caen Normandie
Caen, France
Crlcc Francois Baclesse
Caen, France
Hopital Estaing - Chu63 - Clermont Ferrand
Clermont-Ferrand, France
Hu Paris Nord Site Louis Mourier Aphp
Colombes, France
Hopital Le Bocage Chru Dijon
Dijon, France
Chu de Grenoble Alpes
Grenoble, France
Hop Claude Huriez Chu Lille
Lille, 59045, France
Clcc Oscar Lambret Lille
Lille, France
C H U Dupuytren Limoges
Limoges, France
Hospices Civils de Lyon (Pierre Bénite,Edouard Herriot, La Croix Rousse)
Lyon, France
Aphm Hopital Nord
Marseille, France
Hopital St Eloi Chu Montpellier
Montpellier, France
Icm - Montpellier
Montpellier, France
Chu de Nantes :Site Hôtel-Dieu- Hme
Nantes, France
Chu Nimes
Nîmes, France
Hu Est Parisien Site St Antoine Aphp
Paris, France
Hu Paris Centre Site Cochin Aphp
Paris, France
Hu Paris Sud Site Kremlin Bicetre Aphp
Paris, France
Hu Saint Louis Site Saint Louis Aphp
Paris, France
Hopital Haut-Leveque - Chu - Pessac
Pessac, 33604, France
Hopital Robert Debre Chu Reims
Reims, France
Chru Rennes Site Pontchaillou
Rennes, France
Hopital Charles Nicolle Chu Rouen
Rouen, France
Hus/Hop Hautepierre
Strasbourg, France
Hopital Purpan Chu
Toulouse, France
Chu de Tours
Tours, France
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, France
Institut Gustave Roussy
Villejuif, France
Related Publications (1)
Mariette C, Renaud F, Piessen G, Gele P, Copin MC, Leteurtre E, Delaeter C, Dib M, Clisant S, Harter V, Bonnetain F, Duhamel A, Christophe V, Adenis A; Fregat Working Group. The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers. BMC Cancer. 2018 Feb 6;18(1):139. doi: 10.1186/s12885-018-3991-8.
PMID: 29409462DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Guillaume Piessen, MD, PhD
University Hospital, Lille
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 13 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 13, 2015
First Posted
August 18, 2015
Study Start
June 1, 2014
Primary Completion (Estimated)
May 1, 2027
Study Completion (Estimated)
May 1, 2027
Last Updated
September 11, 2020
Record last verified: 2020-09
Data Sharing
- IPD Sharing
- Will not share